Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.

[1]  R. Grais,et al.  Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. , 2019, Vaccine.

[2]  Amanda J. Lee,et al.  The Dual Nature of Type I and Type II Interferons , 2018, Front. Immunol..

[3]  N. Beare,et al.  Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic, Sierra Leone , 2018, Emerging infectious diseases.

[4]  H. Feldmann,et al.  The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials , 2018, Human vaccines & immunotherapeutics.

[5]  Chi-Chao Chan,et al.  ZIKA virus infection causes persistent chorioretinal lesions , 2018, Emerging Microbes & Infections.

[6]  X. Qiu,et al.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine , 2018, Expert opinion on biological therapy.

[7]  P. Creisher,et al.  The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon-gamma expression and a Th1-like cytokine profile , 2017, Journal of Neuroimmunology.

[8]  K. Peden,et al.  Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout. , 2017, Vaccine.

[9]  M. Kieny,et al.  Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial , 2017, PLoS medicine.

[10]  Bryan R. Smith,et al.  Cerebrospinal Fluid Examination in Survivors of Ebola Virus Disease , 2017, JAMA neurology.

[11]  W. J. Ramsey,et al.  Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. , 2017, The Lancet. Infectious diseases.

[12]  N. Beare,et al.  Novel Retinal Lesion in Ebola Survivors, Sierra Leone, 2016 , 2017, Emerging infectious diseases.

[13]  P. T. Ten Eyck,et al.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice , 2017, Journal of Virology.

[14]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.

[15]  A. N. van den Pol,et al.  Zika Virus Targeting in the Developing Brain , 2017, The Journal of Neuroscience.

[16]  A. N. van den Pol,et al.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain , 2017, Journal of Virology.

[17]  Ali Khademhosseini,et al.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead , 2017, Critical reviews in biotechnology.

[18]  V. Pavot.  Ebola virus vaccines: Where do we stand? , 2016, Clinical immunology.

[19]  D. Verthelyi,et al.  Zika (PRVABC59) Infection Is Associated with T cell Infiltration and Neurodegeneration in CNS of Immunocompetent Neonatal C57Bl/6 Mice , 2016, PLoS pathogens.

[20]  G. Wilkie,et al.  Late Ebola virus relapse causing meningoencephalitis: a case report , 2016, The Lancet.

[21]  T. Fletcher,et al.  Ebola virus disease and critical illness , 2016, Critical Care.

[22]  T. Burki.  Post-Ebola syndrome. , 2016, The Lancet. Infectious diseases.

[23]  M. Diamond,et al.  Understanding How Zika Virus Enters and Infects Neural Target Cells. , 2016, Cell stem cell.

[24]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[25]  F. Sahr,et al.  Post-Ebola Syndrome, Sierra Leone , 2016, Emerging infectious diseases.

[26]  R. Fowler,et al.  Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. , 2016, The Lancet. Infectious diseases.

[27]  H. Feldmann,et al.  Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines. , 2015, The Journal of infectious diseases.

[28]  S. Yerly,et al.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.

[29]  J. Strong,et al.  VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain , 2015, Science.

[30]  S. Baize,et al.  Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Justine R. Smith,et al.  Persistence of Ebola Virus in Ocular Fluid during Convalescence. , 2015, The New England journal of medicine.

[32]  K. Mansfield,et al.  Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates , 2012, PLoS neglected tropical diseases.

[33]  A. Basu,et al.  Viral infection and neural stem/progenitor cell's fate: Implications in brain development and neurological disorders , 2011, Neurochemistry International.

[34]  G. Prince,et al.  Control of RSV-induced lung injury by alternatively activated macrophages is IL-4Rα-, TLR4-, and IFN-β-dependent , 2010, Mucosal Immunology.

[35]  Steven J M Jones,et al.  Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates , 2008, PLoS pathogens.

[36]  M. Puig,et al.  CpG Oligodeoxynucleotides Protect Newborn Mice from a Lethal Challenge with the Neurotropic Tacaribe Arenavirus , 2006, The Journal of Immunology.

[37]  D. Griffin,et al.  Characterization of an In Vitro Model of Alphavirus Infection of Immature and Mature Neurons , 2005, Journal of Virology.

[38]  J. Whitton,et al.  Coxsackievirus Targets Proliferating Neuronal Progenitor Cells in the Neonatal CNS , 2005, The Journal of Neuroscience.

[39]  H. Feldmann,et al.  Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses , 2004, Journal of Virology.

[40]  D. Hassett,et al.  Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. , 2003, The American journal of pathology.

[41]  A. Roberts,et al.  Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[42]  G. Sirera,et al.  Leishmania/HIV co-infection in south-western Europe 1990-1998 Retrospective analysis of 965 cases , 2000 .